Content by Lonza

Learn how visualizing angiogenesis in real time supports drug development.

New methods for deriving macrophages from induced pluripotent stem cells are easier to scale and provide more clinically relevant data.

In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based assays.

The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex^® Biopark in Visp (CH).

CASGEVY^® is the first cell therapy based on the CRISPR/Cas9 technology, discoverers of which were awarded the Nobel Prize in Chemistry in 2020.

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

Discover how implementation of next-generation Manufacturing Execution Systems (MES) can be optimized and streamlined to pave the way to faster pharma digitalization.

On 12 November, Lonza will host a free 60-minute webinar during which Nephron Pharmaceuticals will explain its decision to take a paperless approach to batch record management. Nephron will also discuss how its close relationship with Lonza allowed for a rapid implementation of Lonza's MODA-ES™ Electronic Batch Record (EBR) Platform in just nine months, leading to increased operational efficiency and expanded product lines.

·        Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting
· The MODA-ES™ Platform was implemented at Nephron in an aggressive nine-month time frame, improving operational efficiency and enabling a significant product line expansion
·        Full results of the collaboration will be co-presented by Lonza and Nephron at the 2019 ISPE Annual Meeting & Expo in Las Vegas, Nevada

Lonza has introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs. Researchers across pharmaceutical and contract manufacturing organizations can now choose from an extensive range of services, including cell-line expansion and banking, media production, cell isolation, cell characterization, transfection services, and 3-dimensional (3D) cell-culture services.

Lonza has further strengthened its extensive mycoplasma detection portfolio with the addition of the Lucetta™ 2 Luminometer, a single-tube system designed to simplify and accelerate mycoplasma detection in cell cultures. Pharmaceutical, biotechnology and academic researchers can now rely on this compact, portable and easy-to-use instrument to run Lonza’s MycoAlert™ Mycoplasma Detection Assays and obtain highly reliable results within just 20 minutes.

Lonza announces the launch of DonorPlex™ Hepatocytes, a new line of high-quality cryopreserved pooled donor suspension hepatocytes, which are the first of their kind to be produced using Lonza’s novel patented manufacturing process. Researchers within DMPK and ADME laboratories can now benefit from this reliable and robust product offering for studying the hepatic metabolism of drugs.

Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables cell biologists to easily access a wide selection of high-quality cells to boost their scientific research.

Today Lonza announced the latest addition to its cell-culture product portfolio – the Quasi Vivo® System. The Quasi Vivo® Device consists of an advanced, interconnected fluidics system to create more physiologically relevant cell-culture conditions, helping researchers improve the predictive value of their studies.

During the Society of Toxicology Meeting from 11-15 March 2018 at the Henry B. González Convention Center in San Antonio, TX (USA), Lonza will present two posters highlighting its latest research into developing more physiologically relevant in vitro cell-culture models for ADME-Tox testing.